December PharmaPendium™ release contains the fully integrated Chemistry Structure Editor and Search Technology and the new PharmaPendium Published Toxicity Database

Chemistry Structure Editor & Search Technology

PharmaPendium with the new integrated Chemistry Structure Editor means that users will now no longer be required to download and install the chemistry drawing tool.

Instead, PharmaPendium now comes with a self-contained chemistry structure editor for drawing and manipulating chemical structures. In addition PharmaPendium now employs the Reaxys® chemistry search technology. No software downloading will be required; the Chemistry Structure Editor will open within the search browser for an improved product experience.

Users who have their own chemical drawing tool will be able to upload their own .mol files.

View an example of the new sketcher

PharmaPendium Published Toxicity Database

In response to customer feedback PharmaPendium has re-mapped over 150,000 FDA and EMA preclinical data points to more specific categorization. This re-mapping will improve your ability to see which preclinical animal data best translates to clinical and post-marketing effects.

As a part of the same effort, we will be adding the PharmaPendium Published Toxicity database. This will replace the current database used in PharmaPendium for preclinical published toxicity.The new database will be more precise in its mapping, more comprehensive in its extraction process from published articles and will contain a much improved set of links back to the cited article.

Summary of December release:

• New preclinical toxicity mapping for over 150,000 extracted FDA and EMA data points for better specificity and better translation analysis.
• A much higher percentage of extracted published data with resolvable links back to the cited article.
• The January 2011 release of the database will already cover more drugs, and be more specific than the previous published content source.
• New fully integrated Chemistry Structure Editor & Search Technology

The December content releases include the following content updates:
FDA Approval Packages:

• 9 new drugs:
      - Alcaftadine
      - Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil
      - Buprenorphine
      - Cabazitaxel
      - Denosumab
      - Formoterol Fumarate; Mometasone Furoate
      - Hexaminolevulinate Hydrochloride
      - Incobotulinumtoxina Sodium Sulfate; Potassium Sulfate; Magnesium Sulfate

• 834 new FDA Approval Documents, including documents for 31 Approval Packages
• 24,526 new pages of FDA Approval Documents

EMA:

• 8 new drugs: Alendronic Acid; Colecalciferol Amifampridine Corifollitropin Alfa Epoetin Theta Human Hepatitis B Immunoglobulin Indacaterol Maleate Prucalopride Roflumilast
• 171 new EMA Documents
• 3,748 new pages of EMA Documents

Extracted Safety data observations:

• 22,129 new extracted safety data lines

Complete remapping of RTECS toxic effect codes to MedDRA terms provided. Extracted PK data observations:

• 128,190 new extracted PK data lines

FDA Advisory Committee Documents:

• 971 new documents
• 52,055 new pages

Published Toxicity Database:

• 1,413 drugs
• 14,198 safety records

AERS (post-marketing) reports:

• 126,484 new reports

This brings the new totals for PharmaPendium to the following:

• 1,420,070 pages of FDA Approval documents (Including FDA Classic Collection)
• 59,546 FDA Approval documents (Including FDA Classic Collection)
• 4052 Drugs with data in PharmaPendium (Please note: total number of drugs 4073; 21 of them have no data)
• 957,401 extracted data lines in the Drug Safety database
• 1,028,125 extracted PK data lines
• 3,426,613 AERS (post-marketing) reports
• 3,800 documents / 67,793 pages of EMA Approval documents
• 10,906 documents / 308,015 pages of FDA Classic Collection
• 9,552 documents / 384,476 pages of FDA Advisory Committee Meeting documents